Physician profile
Mark D Henin
NPI 1962793422
$1,107.65
in general payments reported to CMS, 2019-2025
20 companies · $186 in 2025
The $186 reported for 2025 was less than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $373 · 2020: $66.10 · 2022: $108 · 2023: $241 · 2024: $133 · 2025: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $560.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $192.60 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Dexcom, INC. | $123.45 | 2019-2023 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $115.49 | 2019-2023 | Norditropin |
| Ascendis Pharma Endocrinology INC | $100.07 | 2022-2024 | |
| Medtronic Minimed, INC. | $64.98 | 2019 | |
| Abbvie INC. | $57.32 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $54.57 | 2019 | |
| Pfizer INC. | $50.63 | 2023-2024 | |
| Medtronic, INC. | $43.77 | 2023 | Minimed 780g |
| Sanofi-Aventis U.S. LLC | $42.21 | 2023-2024 | |
| Abbott Laboratories | $40.79 | 2023-2024 | Freestyle Libre 3 |
| Insulet Corporation | $40.24 | 2019-2025 | Omnipod |
| Tolmar, INC. | $29.97 | 2023 | |
| Arbor Pharmaceuticals, INC. | $27.68 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $24.57 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $24.39 | 2019 | |
| Ibsa Pharma INC. | $23.36 | 2022 | |
| Azurity Pharmaceuticals, INC. | $22.48 | 2024 | Triptodur |
| Ferring Pharmaceuticals INC. | $14.77 | 2019 | |
| Companion Medical, INC. | $14.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Henin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.